

Antitumor Molecular-Targeted Agents

Many past antitumor agents have predominately operated as non-specific cytotoxic tubulin inhibitors that, while successful have suffered from numerous drawbacks stemming from this non-specificity.¹⁾ Modern antitumor agents such as imatinib²⁾ and regorafenib³⁾ sought to improve upon these limitations by functioning as targeted kinase inhibitors and have improved side effect profiles and pose less hazards than tubulin inhibitors. Thalidomide and pomalidomide have recently been shown to possess antitumor activities through its vascular endothelial growth factor (VEGF) inhibition. TCI provides high quality pharmaceutical reagents for investigate research and biomedical applications.

Afatinib (>97.0%)	50mg / 250mg [A2870]
BMS-599626 (>98.0%)	10mg / 50mg [B5520]
Bortezomib (>98.0%)	10mg / 50mg [B5741]
Gefitinib (>98.0%)	1g / 5g [G0546]
Imatinib (>98.0%)	100mg / 1g [I0906]
Imatinib Mesylate (>98.0%)	100mg / 1g [I0936]
Lapatinib (>98.0%)	250mg / 1g [L0360]
L-778123 Dihydrochloride (>98.0%)	5mg / 25mg [L0337]
Mubritinib (>98.0%)	25mg / 100mg [M3058]
Pazopanib Hydrochloride (>95.0%)	50mg / 250mg [P2243]
Pelitinib (>97.0%)	25mg / 100mg [P2529]
Regorafenib (>98.0%)	25mg / 100mg [R0142]
Temsirolimus (>95.0%)	10mg / 50mg [T3574]
Lenalidomide (>98.0%)	250mg / 1g [L0332]
Pomalidomide (>98.0%)	25mg / 100mg [P2074]
(±)-Thalidomide (>98.0%)	1g / 5g [T2524]

For Laboratory Use, Research Purposes Only.

- References**
- 1) J. R. Jackson, D. R. Patrick, M. M. Dar and P. S. Huang, *Nat. Rev. Cancer* **2007**, 7, 107.
<http://doi.org/10.1038/nrc2049>
 - 2) R. Capdeville, E. Buchdunger, J. Zimmermann, A. Matter, *Nat. Rev. Drug Discovery* **2002**, 1, 493.
<http://doi.org/10.1038/nrd839>
 - 3) D. Strumberg, B. Schultheis, *Expert Opin. Invest. Drugs* **2012**, 21, 879.
<http://doi.org/10.1517/13543784.2012.684752>
 - 4) J. B. Bartlett, K. Dredge, A. G. Dalglish, *Nat. Rev. Cancer* **2004**, 4, 314.
<http://doi.org/10.1038/nrc1323>

More references can be found on the application page for each product on TCI website.

For further information please refer to our website at www.TCIchemicals.com.

TCI antitumor

Ordering and Customer Service

TCI AMERICA

Tel : 800-423-8616 / 503-283-1681
Fax : 888-520-1075 / 503-283-1987
E-mail : Sales-US@TCIchemicals.com

TCI EUROPE N.V.

Tel : +32 (0)3 735 07 00
Fax : +32 (0)3 735 07 01
E-mail : Sales-EU@TCIchemicals.com

TCI Deutschland GmbH

Tel : +49 (0)6196 64053-00
Fax : +49 (0)6196 64053-01
E-mail : Sales-DE@TCIchemicals.com

Tokyo Chemical Industry UK Ltd.

Tel : +44 (0)1865 78 45 60
E-mail : Sales-UK@TCIchemicals.com

梯希爱(上海)化成工业发展有限公司

Tel : 800-988-0390 / 021-67121386
Fax : 021-6712-1385
E-mail : Sales-CN@TCIchemicals.com

Tokyo Chemical Industry (India) Pvt. Ltd.

Tel : 1800 425 7889 / 044-2262 0909
E-mail : Sales-IN@TCIchemicals.com

TOKYO CHEMICAL INDUSTRY CO., LTD.

Tel : +81 (0)3-5640-8878
E-mail : globalbusiness@TCIchemicals.com

Availability, price or specification of the listed products are subject to change without prior notice. Reproduction forbidden without the prior written consent of Tokyo Chemical Industry Co., Ltd.